Corona booster

In the 2024/25 season, one dose will be given regardless of previous vaccination. However, the vaccine must be given at least 3 months after the last Covid vaccination.

Vaccination against COVID-19 and influenza can be administered and given simultaneously or at any interval. When administering multiple vaccines that are given intramuscularly, these can be given in the deltoid muscle. There must be at least 2 cm between each injection site (taking into account avoiding injecting too close to the acromion). The vaccines must never be mixed in the same syringe.

Vaccine content

The vaccine consists of messenger RNA (mRNA), in the form of purified messenger RNA produced via cell-free in vitro transcription from the corresponding DNA templates encoding the spike protein in SARS-CoV-2 (JN. 1).

A complete list of excipients can be found in the summary of product characteristics.

The target group for vaccination

The vaccine is approved for people from 6 months of age.

In the 2024-2025 season, vaccination is recommended for everyone over 65 years of age, and adults under 65 years of age at risk of a severe course, as well as for people in the same household as people with immunodeficiency. For further information, see the Danish Health Authority's guidelines.

Children and young people who are at particularly increased risk of a serious course of COVID-19 will also be able to be vaccinated after a specific, individual assessment by a pediatric specialist.

Vaccination dose

The vaccine is available in different formulations and dosages:

For adults and adolescents over 12 years of age: One dose (0.3 ml) contains 30 micrograms of Bretovameran COVID-19 mRNA vaccine. (Gray cap)

For children from 5 years to 11 years of age: One dose (0.3 ml) contains 10 micrograms of Bretovameran COVID-19 mRNA vaccine. (Blue cap)

For children 6 months to 4 years of age: One dose (0.3 ml) contains 3 micrograms of Bretovameran COVID-19 mRNA vaccine. (Yellow cap)

Booster vaccination with Comirnaty JN. 1 can be given no earlier than 3 months after the last dose of Covid vaccine.

The vaccine is injected intramuscularly into the deltoid muscle (m. deltoideus).

Who should not be vaccinated?

People with severe allergies to one or more of the ingredients.

In case of acute illness or fever above 38°C, vaccination should be postponed.

As with other intramuscular injections, the vaccine should be administered with caution to individuals receiving anticoagulant therapy or who have thrombocytopenia or a coagulation disorder (such as haemophilia) as bleeding or bruising may occur following an intramuscular injection in these individuals.

People who have had serious side effects from previous vaccination with the vaccine should contact a doctor for assessment before vaccination.

Individuals who have previously experienced an immediate anaphylactic reaction following vaccination or injection of a medicinal product should be assessed by a physician before being vaccinated with Comirnaty JN. 1, as they are at increased risk of an allergic reaction. Assessment may be made by a physician prior to vaccination, who may, if appropriate, consult a specialist allergy centre.

See questions and answers about Covid vaccination.

In case of doubt, please seek medical advice.

Pregnancy and breastfeeding

Comirnaty JN. 1 can be used during pregnancy and breastfeeding.

Pregnant women are generally recommended to be vaccinated in the 2nd or 3rd trimester. If the pregnant woman has not previously been vaccinated against COVID-19 or has other risk factors for a severe course of COVID-19, vaccination is recommended in the 1st trimester.

For further information, please contact your doctor, health visitor or midwife.

Most common side effects

Pain and swelling at the injection site, headache, muscle pain, joint pain, diarrhoea and fever are very common side effects. Redness at the injection site, swollen lymph nodes, nausea and vomiting are also common. Very rare cases of myocarditis and pericarditis have been observed after vaccination with Comirnaty. Healthcare professionals should be alert for signs and symptoms such as (acute and persistent) chest pain, shortness of breath or palpitations.

Reporting of side effects - stricter reporting obligation:

As the vaccine has not been used previously (new variant), the Danish Medicines Agency has decided that Comirnaty JN. 1 is subject to a strict reporting obligation, which means that doctors are obliged to report all suspected side effects in people who have been vaccinated. The strict reporting obligation lasts 2 years after introduction.

Suspected side effects must be reported to the Danish Medicines Agency no later than 15 days after the doctor has received the suspicion, and can be reported via meldenbivirkning.dk .

For further details, please refer to the Summary of Product Characteristics.

Duration of protection

The duration of protection is unknown.

The State Serum Institute (2024), https://www.ssi.dk/vaccinationer/vaccineleksikon/c/covid-19-vaccine-pfizer-biontech-variantopdateret-comirnaty-jn-1